Anne Nobles's Insider Trades & SAST Disclosures
Anne Nobles's most recent trade in Lilly(Eli) & Co was a trade of 6,828 Common Stock done at an average price of $869.0 . Disclosure was reported to the exchange on Feb. 10, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Anne Nobles.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Lilly(Eli) & Co | Anne Nobles | EVP & Pres, Lilly Neuroscience | Grant, award, or other acquisition of securities at price $ 868.99 per share. | 10 Feb 2025 | 6,828 | 74,209 (0%) | 0% | 869.0 | 5,933,469 | Common Stock |
| Lilly(Eli) & Co | Anne Nobles | EVP & Pres, Lilly Neuroscience | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2025 | 3,572 | 3,572 | - | - | Restricted Stock Unit | |
| Lilly(Eli) & Co | Anne Nobles | EVP & Pres, Lilly Neuroscience | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2025 | 3,269 | 0 | - | - | Restricted Stock Unit | |
| Lilly(Eli) & Co | Anne Nobles | EVP & Pres, Lilly Neuroscience | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2025 | 3,269 | 68,838 (0%) | 0% | 0 | Common Stock | |
| Lilly(Eli) & Co | Anne Nobles | EVP & Pres, Lilly Neuroscience | Payment of exercise price or tax liability using portion of securities received from the company at price $ 811.14 per share. | 01 Feb 2025 | 1,457 | 67,380 (0%) | 0% | 811.1 | 1,181,826 | Common Stock |
| Lilly(Eli) & Co | Anne Nobles | EVP & Pres, Lilly Neuroscience | Grant, award, or other acquisition of securities at price $ 737.26 per share. | 12 Feb 2024 | 5,363 | 65,569 (0%) | 0% | 737.3 | 3,953,925 | Common Stock |
| Lilly(Eli) & Co | Nobles Anne | EVP & Pres, Lilly Neuroscience | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2024 | 3,269 | 3,269 | - | - | Restricted Stock Unit | |
| Lilly(Eli) & Co | Nobles Anne | EVP & Pres, Lilly Neuroscience | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2024 | 4,124 | 0 | - | - | Restricted Stock Unit | |
| Lilly(Eli) & Co | Anne Nobles | EVP & Pres, Lilly Neuroscience | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2024 | 4,124 | 62,050 (0%) | 0% | 0 | Common Stock | |
| Lilly(Eli) & Co | Anne Nobles | EVP & Pres, Lilly Neuroscience | Payment of exercise price or tax liability using portion of securities received from the company at price $ 645.61 per share. | 01 Feb 2024 | 1,844 | 60,206 (0%) | 0% | 645.6 | 1,190,505 | Common Stock |
| Lilly(Eli) & Co | Anne Nobles | EVP & Pres, Lilly Neuroscience | Grant, award, or other acquisition of securities at price $ 345.12 per share. | 10 Feb 2023 | 8,562 | 62,926 (0%) | 0% | 345.1 | 2,954,917 | Common Stock |
| Lilly(Eli) & Co | Anne Nobles | EVP & Pres, Lilly Neuroscience | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2023 | 4,124 | 4,124 | - | - | Restricted Stock Unit | |
| Lilly(Eli) & Co | Anne Nobles | EVP & Pres, Lilly Neuroscience | Sale of securities on an exchange or to another person at price $ 342.76 per share. | 10 Feb 2023 | 2,500 | 60,426 (0%) | 0% | 342.8 | 856,900 | Common Stock |
| Lilly(Eli) & Co | Anne Nobles | EVP & Pres, Lilly Neuroscience | Sale of securities on an exchange or to another person at price $ 346.47 per share. | 10 Feb 2023 | 2,500 | 57,926 (0%) | 0% | 346.5 | 866,175 | Common Stock |
| Lilly(Eli) & Co | Anne Nobles | EVP & Pres, Lilly Neuroscience | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2023 | 7,264 | 0 | - | - | Restricted Stock Unit | |
| Lilly(Eli) & Co | Anne Nobles | EVP & Pres, Lilly Neuroscience | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2023 | 7,264 | 57,616 (0%) | 0% | 0 | Common Stock | |
| Lilly(Eli) & Co | Anne Nobles | EVP & Pres, Lilly Neuroscience | Payment of exercise price or tax liability using portion of securities received from the company at price $ 344.15 per share. | 01 Feb 2023 | 3,252 | 54,364 (0%) | 0% | 344.2 | 1,119,176 | Common Stock |
| Lilly(Eli) & Co | Anne Nobles | SVP & Pres-Lilly Neuroscience | Grant, award, or other acquisition of securities at price $ 243.27 per share. | 09 Feb 2022 | 11,348 | 50,352 (0%) | 0% | 243.3 | 2,760,628 | Common Stock |
| Lilly(Eli) & Co | Anne Nobles | SVP & Pres-Lilly Neuroscience | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2022 | 7,264 | 7,264 | - | - | Restricted Stock Unit | |
| Lilly(Eli) & Co | Anne Nobles | SVP & Pres-Lilly Neuroscience | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2022 | 9,368 | 0 | - | - | Restricted Stock Unit | |
| Lilly(Eli) & Co | Anne Nobles | SVP & Pres-Lilly Neuroscience | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2022 | 9,368 | 43,208 (0%) | 0% | 0 | Common Stock | |
| Lilly(Eli) & Co | Anne Nobles | SVP & Pres-Lilly Neuroscience | Payment of exercise price or tax liability using portion of securities received from the company at price $ 245.39 per share. | 01 Feb 2022 | 4,204 | 39,004 (0%) | 0% | 245.4 | 1,031,620 | Common Stock |
| Lilly(Eli) & Co | Anne Nobles | SVP & Pres-Lilly Oncology | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2021 | 9,368 | 9,368 | - | - | Restricted Stock Unit | |
| Lilly(Eli) & Co | Anne Nobles | SVP & Pres-Lilly Oncology | Grant, award, or other acquisition of securities at price $ 205.77 per share. | 08 Feb 2021 | 4,718 | 33,840 (0%) | 0% | 205.8 | 970,823 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges